Tilapia Lake Virus (TiLV) is recognized as one of the most important viral threats to the global tilapia aquaculture industry, especially to Nile tilapia (Oreochromis niloticus). TiLV is a negative-sense RNA virus classified as a member of the family Amnoonviridae. This virus targets vital organs such as the liver and brain, leading to syncytial hepatitis, hepatocellular necrosis, systemic infection, and a short incubation period. Fry and juvenile tilapia are highly susceptible to TiLV, making hatchery and nursery systems highly vulnerable to devastating outbreaks. At present, there are limited control strategies to combat this devastating tilapia disease, and although antibiotics are of no use in combating this viral infection, the use of vaccine is still under evaluation. Recent scientific findings suggest that seaweed bioactive compounds are a new class of natural antiviral substances that are effective in controlling TiLV. In this context, the antiviral effect of marine macroalgal extracts has been proven to show a positive effect in vitro and in vivo. Seaweed supplements are known to show a positive effect in tilapia, and dietary seaweed supplements are known to show a positive effect in tilapia, which helps to improve hematological parameters, innate immunity, antioxidant enzyme activities, and antiviral gene expression.